FREE Shipping for orders above $80
My Account
Need Help?




Scientific References

  1. Cantoni GL. The nature of the active methyl donor formed enzymatically from L-methionine and adenosine triphosphate. J Am Chem Soc 1952;74:2942–3.
  2. Cheng X, Blumenthal RM. S-Adenosylmethionine-dependent methyltransferases: structures and functions. World Scientific Publication Co, 1999.
  3. Chiang PK, Gordon RK, Tal J, et al. S-Adenosylmethionine and methylation. FASEB J 1996;10:471–80.
  4. Janicak PG, Lipinski JD, Comaty JE, et al. S-Adenosylmethionine: a literature review and preliminary report. Ala J Med Sci 1988;25:306–13.
  5. Friedel HA, Goa KL, Benfield P. S-Adenosyl-L-methionine: a review of its therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389–416.
  6. Bressa GM. S-Adenosyl-L-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand 1994;154:7–14.
  7. Bradley JD, Flusser D, Katz BP, et al. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J Rheumatol 1994;21:905–11.
  8. Padova C. S-Adenosylmethionine in the treatment of osteoarthritis: review of the clinical studies. Am J Med 1987;83:60–5.
  9. Lieber CS. Role of S-adenosyl-L-methionine in the treatment of liver diseases. J Hepatol 1999;30:1155–9.
  10. Williams R, Lieber CS. The role of SAMe in the treatment of liver disease. Drugs 1990;40(suppl):1–2.
  11. Mato JM, Camara J, Fernandez de Paz J, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081–9.
  12. Brown R, Gerbarg P, Bottiglieri T. S-Adenosylmethionine in the clinical practice of psychiatry, neurology and internal medicine. Clin Pract Intern Med 2000;1:230–41.
  13. Paulsen M, Ferguson-Smith AC. DNA methylation in genomic imprinting, development, and disease. J Pathol 2001;195:97–110.
  14. Momparler RL, Bovenci V. DNA methylation and cancer. J Cell Physiol 2000;183:145–54.
  15. Billingsley ML, Balaban CD. Protein-O-carboxylmethyltransferase in the rat brain: high regional levels in the substantia nigra, locus coeruleus and paraventricular nucleus. Brain Res 1985;358:96–103.
  16. Clarke S. Perspectives on the biological function and enzymology of protein carboxyl methylation reactions in eucaryotic and procaryotic cells. Adv Exp Med Biol 1988;231:213–28.
  17. Hirata F, Viveros OH, Diliberto EJ Jr, Axelrod J. Identification and properties of two methyltransferases in conversion of phosphatidylethanolamine to phosphatidylcholine. Proc Natl Acad Sci U S A 1978;75:1718–21.
  18. Crews FT. Effects of membrane fluidity on secretion and receptor stimulation. Psychopharmacol Bull 1982;18:135–43.
  19. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41–0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997;20:55–66.
  20. Cheng H, Gomes-Trolin C, Aquilonius SM, et al. Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson’s disease. Exp Neurol 1997;145:580–5.
  21. Surtees R, Hyland K. L-3,4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans. J Neurol Neurosurg Psychiatry 1990;53:569–72.
  22. Taylor KM, Randall PK. Depletion of S-adenosyl-L-methionine in mouse brain by antidepressive drugs. J Pharmacol Exp Ther 1975;194:303–10.
  23. Mudd SH, Pool JH. Labile methyl balances from normal humans on various dietary regimens. Metabolism 1975;24:721–35.
  24. Finkelstein JD, Martin JJ, Harris BJ. Methionine metabolism in mammals. The methionine-sparing effect of cystine. J Biol Chem 1988;263:11750–4.
  25. Womack M, Rose WC. Partial replacement of dietary methionine by cysteine for purposes of growth. J Biol Chem 1941;141:375–9.
  26. Finkelstein JD, Martin JJ. Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. J Biol Chem 1984;259:9508–13.
  27. Della Ragione F, Pegg AE. Effect of analogues of 5′-methylthioadenosine on cellular metabolism. Inactivation of S-adenosylhomocysteine hydrolase by 5′-isobutylthioadenosine. Biochem J 1983;210:429–35.
  28. Herby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981;19:1–20.
  29. Oyanagui Y. Anti-inflammatory effects of polyamines in serotonin and carrageenan paw edemata—possible mechanism to increase vascular permeability inhibitory protein level which is regulated by glucocorticoids and superoxide radical. Agents Actions 1984;14:228–37.
  30. Stramentinoli G, Gualano M, Galli-Kienle M. Intestinal absorption of S-adenosyl-L-methionine. J Pharmacol Exp Ther 1979;209:323–6.
  31. Bottiglieri T, Chary TKN, Laundy M, et al. Transmethylation and depression. Ala J Med Sci 1988;25:296–300.
  32. Stramentinoli G. Ademethionine as a drug. Am J Med 1987;83(suppl):35–42.
  33. Giulidori P, Fellin M, Di Padova C. Metabolism of exogenous S-adenosylmethionine in humans and its significance in the therapeutic use of the drug. Proceedings of the workshop Methionine Metabolism: Molecular Mechanisms and Clinical Implications. Madrid, Spain: Jarpyo Editores, 1998:159–63.
  34. Bottiglieri T, Chary TKN, Carney MWP, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: the effect of parenteral and oral treatment. J Neurol Neurosurg Psychiatry 1990;53:1096–8.
  35. Castagna A, Le Grazie C, Giulidori P, Bottiglieri T, Lazzarin A. Deficiency of CSF S-adenosylmethionine (SAMe) and glutathione in HIV infected patients: the effect of parenteral treatment with SAMe. Neurology 1995;45:1678–83.
  36. Zappia V, Galletti P, Porcelli M, Ruggiero G, Andreana A. Uptake of adenosylmethionine and related sulfur compounds by isolated rat liver. FEBS Lett 1978;90:331–5.
  37. Horne DW, Holloway RS, Wagner C.Transport of S-adenosylmethionine in isolated rat liver mitochondria. Arch Biochem Biophys 1997;343:201–6.
  38. Fazio C, Andreoli V, Agnoli A, Casacchia M, Cerbo R. Therapeutic effects and mechanism of action of S-adenosyl-L-methionine (SAM) in depressive syndromes. Minerva Med 1973;64:1515–29.
  39. Bottiglieri T. Folate, vitamin B12, and neuropsychiatric disorders. Nutr Rev 1996;54:382–90.
  40. Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders. Clinical potential. Drugs 1993;45:623–36.
  41. Chen Z, Karaplis AC, Ackerman SL, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001;10:433–43.
  42. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228–32.
  43. Algeri S, Catto E, Curcio M, Ponzio F, Stramentinoli G. Changes in rat brain noradrenaline and serotonin after administration of S-adenosylmethionine. In: Zappia V, Usdin E, Salvatore S, eds. Biochemical and pharmacological roles of adenosylmethionine and the central nervous system. New York: Pergamon Press, 1979:81–7.
  44. Otero-Losado ME, Rubio MC. Acute effects of S-adenosyl-L-methionine on catecholaminergic central function. Eur J Pharmacol 1989;163:353–6.
  45. Otero-Losado ME, Rubio MC. Acute changes in 5HT metabolism after S-adenosylmethionine administration. Gen Pharmacol 1989;20:403–6.
  46. Curcio M, Catto E, Stramentinoli G, Algeri S. Effect of SAMe on 5HT metabolism in rat brain. Prog Neuropsychopharmacol 1978;2:65–71.
  47. Bottiglieri T, Laundy M, Martin R, et al. S-Adenosylmethionine influences monoamine metabolism. Lancet 1984;2:224.
  48. Cimino M, Vantini G, Algeri S, Curala G, Pezzoli C, Stramentinoli G. Age-related modification of dopaminergic and beta-adrenergic receptor system: restoration to normal activity by modifying membrane fluidity with S-adenosylmethionine. Life Sci 1984;34:2029–39.
  49. Muccioli G, Scordamaglia A, Bertacco S, Di Carlo R. Effect of S-adenosyl-L-methionine on brain muscarinic receptors. Eur J Pharmacol 1992;227:293–9.
  50. Kowatch MA, Roth GS. Effect of specific membrane perturbations on alpha-adrenergic and muscarinic-cholinergic signal transduction in rat parotid cell aggregates. Life Sci 1994;55:2003–10.
  51. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease. J Neurochem 1996;67:1328–31.
  52. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci U S A 1992;89:1671–5.
  53. Cuenod CA, Kaplan DB, Michot JL, et al. Phospholipid abnormalities in early Alzheimer’s disease. In vivo phosphorus 31 magnetic resonance spectroscopy. Arch Neurol 1995;52:89–94.
  54. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449–55.
  55. Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B(12) and folate in relation to the development of Alzheimer’s disease. Neurology 2001;56:1188–94.
  56. Bottiglieri T, Parnetti L, Arning E, et al. Plasma total homocysteine levels and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene: a study in an Italian population with dementia. Mech Ageing Dev 2001;122:2013–23.
  57. Reynolds EH, Godfrey P, Bottiglieri T, et al. S-Adenosylmethionine in the treatment of Alzheimer’s disease. Neurology 1989;39(suppl):397 (abstr).
  58. Nilsson Knopman D, Patterson M. An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 2001;15:162–5.
  59. Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry 2001;16:609–14.
  60. Passeri M, Cucinotta D, Abate G, et al. Oral 5′-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano) 1993;5:63–71.
  61. Surtees R, Leonard J, Austin S. Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet 1991;338:1550–4.
  62. Surtees R, Hyland K, Smith I. Central-nervous-system methyl-group metabolism in children with neurological complications of HIV infection. Lancet 1990;335:619–21.
  63. Keating JN, Trimble KC, Mulcahy F, Scott JM, Weir DG. Evidence of brain methyltransferase inhibition and early brain involvement in HIV-positive patients. Lancet 1991;337:935–9.
  64. Tan SV, Guiloff RJ. Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. J Neurol Neurosurg Psychiatry 1998;65:23–8.
  65. Petito CK, Navia BA, Cho ES, et al. Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome. N Engl J Med 1985;312:874–9.
  66. Goggins M, Scott JM, Weir DG. Methylation of cortical brain proteins from patients with HIV infection. Acta Neurol Scand 1999;100:326–31.
  67. Horowitz JH, Rypins EB, Henderson JM, et al. Evidence for impairment of transsulfuration pathway in cirrhosis. Gastroenterology 1981;81:668–75.
  68. Duce AM, Ortiz P, Cabrero C, Mato JM. S-Adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 1988;8:65–8.
  69. Ruiz F, Corrales FJ, Miqueo C, Mato JM. Nitric oxide inactivates rat hepatic methionine adenosyltransferase in vivo by S-nitrosylation. Hepatology 1998;28:1051–7.
  70. Corrales FJ, Ruiz F, Mato JM. In vivo regulation by glutathione of methionine adenosyltransferase S-nitrosylation in rat liver. J Hepatol 1999;31:887–94.
  71. Loguercio C, Nardi G, Argenzio F, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol Alcohol 1994;29:597–604.
  72. Galan AI, Munoz ME, Palomero J, Moreno C, Jimenez R. Role of S-adenosylmethionine on the hepatobiliary homeostasis of glutathione during cyclosporine A treatment. J Physiol Biochem 2000;56:189–200.
  73. Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989;24:407–15.
  74. Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. J Hepatol 2000;32(suppl):113–28.
  75. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-Adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther 1997;73:265–80.
  76. Agnoli A, Andreoli V, Casacchia M, Cerbo R. Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiatr Res 1976;13:43–54.
  77. Di Padova C. S-Adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies. Am J Med 1987;83:60–5.
  78. Harmand MF, Vilamitjana J, Maloche E, Duphil R, Ducassou D. Effects of S-adenosylmethionine on human articular chondrocyte differentiation. An in vitro study. Am J Med 1987;83:48–54.
  79. Barcelo HA, Wiemeyer JC, Sagasta CL, Macias M, Barreira JC. Effect of S-adenosylmethionine on experimental osteoarthritis in rabbits. Am J Med 1987;83:55–9.
  80. Vittur F, Lunazzi G, Moro L, et al. A possible role for polyamines in cartilage in the mechanism of calcification. Biochim Biophys Acta 1986;881:38–45.
  81. Gutierrez S, Palacios I, Sanchez-Pernaute O, et al. SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necrosis factor alpha on cultured rabbit synovial cells. Br J Rheumatol 1997;36:27–31.
  82. Trespi A, Vigoni R, Matti C, and et al. TUDCA, UDCA and Ademetionine (Ade) in the treatment of alcohol-induced liver damage [abstract]. J Hepatol 1997;26:128.
  83. Frezza M and Terpin M. The use of S-adenosyl-L-methionine in the treatment of cholestatic disorders: a meta-analysis of clinical trials. Drug Invest 1992;4(Suppl. 4):101-108.
  84. Salvadorini F, Galeone F, Saba P, and et al. Evaluation of S-adenosyl-L-methionine (SAMe) effectiveness on depression. Current Therapeutic Research 1980;27(6 section 2):908-917.
  85. Cergnul I, Jones K, Ernst D, and et al. S-adenosylmethionine (SAM-e) in the treatment of depressive disorders in HIV-positive individuals: interim results [poster]. Poster presentation at the13th National HIV/AIDS update conference 2001;
  86. Chinchilla, M. A., Vega Pinero, M., Cebollada Gracia, A., and et al. Latencia antidepresiva y S-Adenosil-Metionina [Antidepressive latency and S-adenosylmethionine]. Anales de Psiquiatria 1996;12:67-71.
  87. Delle Chiaie R, Panceri P, and Scapicchio P. MC3: multicentre, controlled efficacy and safety trial of oral S-adenosyl-methionine (SAMe) vs. oral imipramine in the treatment of depression. Int J Neuropsychopharmacol 2000;3(Suppl 1):S230.
  88. De Leo D. S-adenosyl-L-methionine (SAMe) in clinical practice: preliminary report on 75 minor depressives. Curr Ther Res 1985;37:658-661.
  89. Bell KM, Potkin SG, Carreon L, and et al. Oral S-adenosylmethionine in the treatment of depression: a double blind, randomized comparison with desipramine. Study Report BioResearch File 1990;
  90. Delle Chiaie R and Boissard G. Meta-analysis of 2 European multicenter controlled trials with ademetionine (SAMe) in major depression [abstract]. Biol Psychiatry 1997;42:245S.
  91. Lafuenti, G., Plotti, G., Nicolanti, G., and et al. Valutazione del rischio ostetrico in gravide con colestasi intraepatica in terapia con S-adenosyl-L-methionine [Evaluation of the obstetrical risk in pregnant women with intrahepatic cholestasis treated with S-adenosyl-L-methionine]. Recenti Prog Med 1988;79:420-423.
  92. Frezza M, Di Padova C, and Italian Study Group for SAMe. Multicenter placebo controlled clinical trial of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease [abstract]. Hepatology 1987;7:1105.
  93. Plasencia AM, Garcia MM, Torres AC, and et al. Total parenteral nutrition plus S-adenosylmethionine in a case of intrahepatic cholestasis. Drug Investigation 1991;3:333-335.
  94. Bradley, J., Flusser, D., Brandt, K., and et al. S-adenosyl methionine (SAMe) in the treatment of osteoarthritis (OA) of the knee. Arthritis Rheum 1991;34(suppl 9):S86.
  95. Stramentinoli, G. and Catto, E. Pharmacokinetic studies of SAMe in several animal species. Pharmacol Res Com 1976;8:211-218.
  96. Bottiglieri, T., Chary, C. K., Laundy, M., and et al. Trans-methylation in depression. Alabama J Med Sci 1988;25:296-301.
  97. Salen, G. and Batta, A. K. Bile acids abnormalities in cholestatic liver diseases. Gastrol Clin 1999;28:173-193.
  98. Vendemiale G, Altomare E, Trizio T, and et al. Effect of S-adenosyl-L-methionine on hepatic glutathione in patients with liver injury. Digestive Diseases and Sciences 1986;31(10 Suppl):92S.
  99. Cantoni, C. J. The Nature of the Active Methyl Donor Formed Enzymatically from L-Methionine and Adenosinetriphosphate. J Am Chem Soc 1952;74:2942-3.
  100. Corrales F, Pajares M, Pliego M, and et al. Effect of S-adenosylmethionine treatment on methionine intolerance in alcoholic cirrhosis [abstract]. J Hepatol 1991;13(Suppl 2):S111.
  101. Altomare E, Vendemiale G Marchesini G Le Grazie C Di Padova C. Increased bioavailability of sulfurated compounds after s-adeno- sylmethionine (SAMe) administration to alcoholics. Biomedical and social aspects of alcohol and alcoholism. 1988;353-356.
  102. Marcolongo R, Giordano N, and Colombo B. Double-blind multicentre study of the activity of S-adenosyl-L-methionine in hip and knee osteoarthritis. Curr Ther Res 1985;37:82-94.
  103. Jellin, J. M., Batz, F., and Hitchens, K. Pharmacist’s letter/prescriber’s letter: Natural Medicines Comprehensive Database. 2001;
  104. Di Palma, D., Fiore, M., Majoli, M., and et al. Prime acquisizioni sul trattamento delle epatiti acute con SAMe [First acquirements on the treatment of the acute hepatitis with SAMe]. G Mal Infett Parassit 1978;30:651-662.
  105. Bresci, G. and Marchioro, M. Effetti della SAMe sugli indici di funzionalità epatica in corso di epatopatia cronica. Confronto con placebo [Effects of SAMe on liver function tests in patients with chronic liver disease. A comparison with placebo]. Gazz Med Ital 1982;141:557-562.
  106. Belmont AD, Henkel RD, and Ancira FU. [Parenteral SAMe as compared to a placebo in the treatment of alcoholic liver disease]. An Med Interna 1996;13:9-15.
  107. Cacciatore L, Varriale A, Cozzolino G, and et al. S-adenosylmethionine (SAMe) in the treatment of pruritus in chronic liver disease. Acta Therapeutica 1989;15:363-371.
  108. Cacciatore L, Cozzolino G, Varriale A, and et al. Treatment of pruritus in chronic liver disease with S-adenosylmethionine [abstract]. European Journal of Clinical Investigation 1989;19(2 pt 2):A15.
  109. Pecoraro, V., Bruno, M., and Giammona, R. L’impiego terapeutico della SAMe (s-adenosil-l-metionina) nella epatite virale acuta [Therapy with SAMe (s-adenosyl-l-methionine) in acute viral hepatitis]. G Mal Infett Parassit 1979;31:390-394.
  110. Mascio G, Guida L, Ferbo U, and et al. Trattamento della steatosi epatica pura o associata ad altre epatopatie. Gazzetta Medica Italiana 1981;140:37-44.
  111. Scarzella R and Appiotti A. Confronto clinico in doppio cieco della SAMe versus clorimipramina nelle sindromi depressive. Rivista Sperimentale di Freniatria 1978;102:359-365.
  112. Del Vecchio M, Iorio G, Cocorullo M, and et al. Has SAMe (Ado-Met) an antidepressant effect? A preliminary trial versus chlorimipramine. Rivista Sperimentale Freniatria 1978;102:344-358.
  113. Criconia AM, Araquistain JM, Daffina N, and et al. Results of treatment with S-adenosyl-L-methionine in patients with major depression and internal illnesses. Curr Ther Res 1994;55:666-674.
  114. Barberi A and Pusateri C. Sugli effetti clinici della S-adenosil-L-metionina (SAMe) nelle sindromi depressive. Minerva Psichiatrica 1978;19:235-243.
  115. Andreoli V, Campedelli A, and Maffei F. La S-adenosil-L-metionina (SAMe) in geropsichiatria: uno studio clinico controllato “in aperto” nelle sindromi depressive dell’eta senile. Giornale di Gerontologia 1977;25:172-180.
  116. Ancarani E, Biondi B, Bolletta A, and et al. Major depression complicating hemodialysis in patients with chronic renal failure: a multicenter, double-blind, controlled clinical trial of S-adenosyl-L-methionine versus placebo. Curr Ther Res 1993;54:680-686.
  117. Agricola R, Dalla Verde G, Urani R, and et al. S-adenosyl-L-methionine in the treatment of major depression complicating chronic alcoholism. Curr Ther Res 1994;55:83-92.
  118. Caroli A. Studio in doppio cieco SAMe (capsule) – Aspirina nell’osteoartrosi. G Clin Med 1980;61:844-857.
  119. Capretto C, Cremona C, and Canaparo L. A double-blind controlled study of S-adenosylmethionine (SAMe) v. ibuprofen in gonarthrosis, coxarthrosis and spondylarthrosis. Clin Trials J 1985;22:15-24.
  120. Marchesini G, Bugianesi E, Bianchi G, and et al. Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. Clinical Nutrition 1992;11:303-308.
  121. Micali M, Chiti D, and Balestra V. Double-blind controlled clinical trial of SAMe administered orally in chronic liver diseases. Curr Ther Res 1983;33:1004-1013.
  122. Roncaglia N, Locatelli A, Bellini P, and et al. A randomized controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. Am J Obstet Gynecol 2000;182(1 pt 2):S167.
  123. Di Benedetto P, Iona LG, and Zidarich V. Clinical evaluation of S-adenosyl-L-methionine versus transcutaneous electrical nerve stimulation in primary fibromyalgia. Curr Ther Res 1993;53:222-229.
  124. Lo Russo, A., Monaco, M., Pani, A., and et al. Efficacy of s-adenosyl-l-methionine in relieving psychologic distress associated with detoxification in opiate users. Curr Ther Res 1994;55:905-913.
  125. Cerutti PG, Savoini G, D’avola G, and et al. Evaluation of the efficacy of s-adenosylmethionine in the treatment of depressive disorders: a controlled clinical trial against minaprine. Basi Razionali della Terapia 1989;19:591-595.
  126. Manzillo G, Piccinino F, Surrenti C, and et al. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease. Drug Invest 1992;4 (Suppl. 4):90-100.
  127. Jorge, A. D. Accion terapeutica de la SAMe en hepatitis aguda [Therapeutic action of the S-adenosyl-L-methionine in acute hepatitis]. Prensa Med Argent 1985;72:373-379.
  128. Carrieri PB, Indaco A, Gentile S, and et al. S-adenosylmethionine treatment of depressioin in patients with Parkinson’s disease: a double-blind, crossover study versus placebo. Curr Ther Res 1990;48:154-160.
  129. Adachi Y, Nanno T, Kanbe A, and et al. The effects of S-adenosylmethionine on intrahepatic cholestasis. Jpn Arch Intern Med 1986;33:185-192.
  130. Frezza M, Cammareri G, Di Padova C, and et al. Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled clinical trial [abstract]. J Hepatol 1987;5 suppl 1:S27.
  131. Catalino F, Scarponi S, Cesa F, and et al. Efficacy and safety of intravenous S-adenosyl-L-methionine therapy in the management of intrahepatic cholestasis of pregnancy. Drug Invest 1992;4(Suppl 4):78-82.
  132. Bortolini M, Catalino F, Scarponi S, and et al. Efficacy and safety of intravenous (IV) S-adenosylmethionine (SAMe) in the management of intrahepatic cholestatis of pregnancy (ICP) [abstract]. Hepatology 1991;14:250A.
  133. Bonfirraro G, Chieffi O, Quinti R, and et al. S-adenosyl-L-methionine (SAMe)-induced amelioration of intrahepatic cholestasis of pregnancy. Results of an open study. Drug Invest 1990;2:125-128.
  134. Delle Chiaie R and Pancheri P. [Combined analysis of two controlled multicentric, double blind studies to assess efficacy and safety of Sulfo-Adenosyl-Methionine (SAMe) vs. placebo (MC1) and SAMe vs. clomipramine (MC2) in the treatment of major depression]. J Ital Psicopatol 1999;5:1-16.
  135. De Vanna M and Rigamonti R. Oral S-adenosyl-L-methionine in depression. Curr Ther Res 1992;52:478-485.
  136. Ianniello A, Ostuni PA, Sfriso P, and et al. S-adenosyl-L-methionine in Sjögren’s syndrome and fibromyalgia. Curr Ther Res 1994;55:699-706.
  137. Cerutti R, Sichel MP, Perin M, and et al. Psychological distress during puerperium: a novel therapeutic approach using S-adenosylmethionine. Curr Ther Res 1993;53:707-716.
  138. Bilton D, Schofield D, Mei G, and et al. Placebo-controlled trials of antioxidant therapy including S-adenosylmethionine in patients with recurrent nongallstone pancreatitis. Drug Invest 1994;8:10-20.
  139. Bombardieri G, Milani A, Bernardi L, and et al. Effects of S-adenosyl-L-methionine (SAMe) in the treatment of Gilbert’s syndrome. Curr Ther Res 1985;37:580-585.
  140. Cibin M, Gentile N, Ferri M, and et al. S-adenosylmethionine (SAMe) is effective in reducing ethanol abuse in an outpatient program for alcoholics. In: Kuriyama K, Takada A, and Ishii H. Biomedical and social aspects of alcohol and alcoholism. Kyoto, Japan: Elsevier Science Publishers BV (Biomedical Division);1988.
  141. De Leo D. S-adenosylmethionine as an antidepressant: a double-blind trial versus placebo. Curr Ther Res 1987;41:865-870.
  142. Gaster B. S-adenosylmethionine (SAMe) for treatment of depression. Alternative Medicine Alert 1999;12:133-135.
  143. Caruso I, Fumagalli M, Boccassini L, and et al. Treatment of depression in rheumatoid arthritic patients. A comparison of S-adenosylmethionine (Samyr*) and placebo in a double-blind study. Clin Trials J 1987;24:305-310.
  144. Agency for Healthcare Research and Quality. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment: Number 64 2002;
  145. Bacq, Y. and Sapey, T. [Pregnancy intrahepatic cholestasis]. Gastroenterol.Clin Biol. 1998;22(8-9):705-713.
  146. Davidson, K. M. Intrahepatic cholestasis of pregnancy. Semin.Perinatol. 1998;22:104-111.
  147. Mato, J. M., Alvarez, L., Ortiz, P., and Pajares, M. A. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther. 1997;73:265-280.
  148. Osman, E., Owen, J. S., and Burroughs, A. K. Review article: S-adenosyl-L-methionine–a new therapeutic agent in liver disease? Aliment Pharmacol Ther 1993;7:21-28.
  149. Agnoli, A., Andreoli, V., Casacchia, M., and Cerbo, R. Effect of s-adenosyl-l-methionine (SAMe) upon depressive symptoms. J Psychiatr.Res 1976;13:43-54.
  150. Bottiglieri, T. and Hyland, K. S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol Scand Suppl 1994;154:19-26.
  151. Kufferle, B. and Grunberger, J. Early clinical double-blind study with S-adenosyl-L-methionine: a new potential antidepressant. Adv.Biochem.Psychopharmacol. 1982;32:175-180.
  152. Muscettola, G., Galzenati, M., and Balbi, A. SAMe versus placebo: a double blind comparison in major depressive disorders. Advances in Biochemical Psychopharmacology 1982;32:151-156.
  153. Pellegrini, P. [S-adenosylmethionine (SAMe) in osteoarthrosis; a double-blind crossover peroral study]. G.Clin Med 1980;61:616-627.
  154. Cucinotta, D., Mancini, M., Ceccato, S., and Castino, E. [Controlled clinical study of SAMe (S-adenosylmethionine) administered orally in degenerative osteoarticular pathology]. G.Clin Med 1980;61:553-566.
  155. Ceccato, S., Cucinotta, D., Carapezzi, C., Ferretti, G., and Passeri, M. [Double-blind clinical study of the therapeutic effect of SAMe and Ibuprofen in degenerative osteoarticular pathology]. G Clin Med 1980;61:148-162.
  156. Scaggion, G., Baldan, L., Domanin, S., Sivo, M., Cenci, I., Beggio, R., and Castorina, G. [Antidepressive action of S-adenosylmethionine compared to nomifensine maleate]. Minerva Psichiatr. 1982;23:93-97.
  157. Giulidori, P., Cortellaro, M., Moreo, G., and Stramentinoli, G. Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. Eur J Clin Pharmacol 1984;27:119-121.
  158. Bacci, Ballerini F., Lopez, Anguera A., Alcaraz, P., and Hernandez, Reyes N. [SAMe in the management of postconcussional syndrome]. Medicina Clinica (Barc.) 1983;80:161-164.
  159. Bottiglieri, T., Laundy, M., Martin, R., Carney, M. W., Nissenbaum, H., Toone, B. K., Johnson, A. L., and Reynolds, E. H. S-adenosylmethionine influences monoamine metabolism. Lancet 7-28-1984;2:224.
  160. Caruso, I., Fumagalli, M., Boccassini, L., Puttini, P. S., Ciniselli, G., and Cavallari, G. Antidepressant activity of S-adenosylmethionine. Lancet 4-21-1984;1:904.
  161. Carney, M. W., Martin, R., Bottiglieri, T., Reynolds, E. H., Nissenbaum, H., Toone, B. K., and Sheffield, B. N. Switch mechanism in affective illness and S-adenosylmethionine. Lancet 4-9-1983;1:820-821.
  162. Calandra, C., Roxas, M., and Rapisarda, V. [Antidepressant action of SAM in comparison to chlorimipramine. Hypotheses to interpret the mechanism of action]. Minerva Psichiatr. 1979;20:147-152.
  163. Monaco, P. and Quattrocchi, F. [Study of the antidepressive effects of a biological transmethylating agent (S-adenosyl-methione or SAM)]. Rivista di Neurologia 1979;49:417-439.
  164. Fazio, C., Andreoli, V., Agnoli, A., Casacchia, M., and Cerbo, R. [Therapeutic effects and mechanism of action of S-adenosyl-L-methionine (SAM) in depressive syndromes]. Minerva Med 4-30-1973;64:1515-1529.
  165. Montrone, F., Fumagalli, M., Sarzi, Puttini P., Boccassini, L., Santandrea, S., Volpato, R., Locati, M., and Caruso, I. Double-blind study of S-adenosyl-methionine versus placebo in hip and knee arthrosis. Clin Rheumatol 1985;4:484-485 .
  166. Miccoli, L., Porro, V., and Bertolino, A. Comparison between the antidepressant activity and of S- adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurol (Napoli) 1978;33 :243-255.
  167. Yousef, I. M., Barnwell, S. G., Tuchweber, B., Weber, A., and Roy, C. C. Effect of complete sulfation of bile acids on bile formation in rats. Hepatology 1987;7:535-542.
  168. Frezza, M., Tritapepe, R., Pozzato, G., and Di Padova, C. Prevention of S-adenosylmethionine of estrogen-induced hepatobiliary toxicity in susceptible women. Am J Gastroenterol 1988;83:1098-1102.
  169. Stramentinoli, G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. Am J Med 11-20-1987;83(5A):35-42.
  170. Carney, M. W., Toone, B. K., and Reynolds, E. H. S-adenosylmethionine and affective disorder. Am J Med 11-20-1987;83(5A):104-106.
  171. Harmand, M. F., Vilamitjana, J., Maloche, E., Duphil, R., and Ducassou, D. Effects of S-adenosylmethionine on human articular chondrocyte differentiation. An in vitro study. Am J Med 11-20-1987;83(5A):48-54.
  172. Potkin, S. G., Bell, K., Plon, L., and Bunney, W. E., Jr. Rapid antidepressant response with SAMe. A double-blind study. Alabama Journal of Medical Sciences 1988;25:313-316.
  173. Rosenbaum, J. F., Fava, M., Falk, W. E., Pollack, M. H., Cohen, L. S., Cohen, B. M., and Zubenko, G. S. An open-label pilot study of oral S-adenosylmethionine in major depression. An interim report. Ala J Med Sci 1988;25:301-306.
  174. Vendemiale, G., Altomare, E., Trizio, T., Le Grazie, C., Di Padova, C., Salerno, M. T., Carrieri, V., and Albano, O. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989;24:407-415.
  175. Everson, G. T., Ahnen, D., Harper, P. C., and Krawitt, E. L. Benign recurrent intrahepatic cholestasis: treatment with S- adenosylmethionine. Gastroenterology 1989;96(5 Pt 1):1354-1357.
  176. Carney, M. W., Edeh, J., Bottiglieri, T., Reynolds, E. M., and Toone, B. K. Affective illness and S-adenosyl methionine: a preliminary report. Clin Neuropharmacol. 1986;9:379-385.
  177. Shafqat, N., Muniz, J. R., Pilka, E. S., Papagrigoriou, E., von, Delft F., Oppermann, U., and Yue, W. W. Insight into S-adenosylmethionine biosynthesis from the crystal structures of the human methionine adenosyltransferase catalytic and regulatory subunits. Biochem.J. 5-15-2013;452:27-36.
  178. Kharbanda, K. K. Methionine metabolic pathway in alcoholic liver injury. Curr.Opin.Clin.Nutr.Metab Care 2013;16:89-95.
  179. Lieber, C. S., Casini, A., DeCarli, L. M., Kim, C. I., Lowe, N., Sasaki, R., and Leo, M. A. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology 1990;11:165-172.
  180. Lu, S. C. and Mato, J. M. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012;92:1515-1542.
  181. Hitchler, M. J. and Domann, F. E. Redox regulation of the epigenetic landscape in cancer: a role for metabolic reprogramming in remodeling the epigenome. Free Radic.Biol.Med. 12-1-2012;53:2178-2187.
  182. Bottiglieri, T., Godfrey, P., Flynn, T., Carney, M. W., Toone, B. K., and Reynolds, E. H. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53:1096-1098.
  183. Nierenberg, A. A., Kansky, C., Brennan, B. P., Shelton, R. C., Perlis, R., and Iosifescu, D. V. Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Aust.N.Z.J.Psychiatry 2013;47:26-42.
  184. Mischoulon, D., Alpert, J. E., Arning, E., Bottiglieri, T., Fava, M., and Papakostas, G. I. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J.Clin.Psychiatry 2012;73:843-848.
  185. Anstee, Q. M. and Day, C. P. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J.Hepatol. 2012;57:1097-1109.
  186. Kharbanda, K. K., Bardag-Gorce, F., Barve, S., Molina, P. E., and Osna, N. A. Impact of altered methylation in cytokine signaling and proteasome function in alcohol and viral-mediated diseases. Alcohol Clin.Exp.Res. 2013;37:1-7.
  187. Jahoor, F. Effects of decreased availability of sulfur amino acids in severe childhood undernutrition. Nutr.Rev. 2012;70:176-187.
  188. Chitiva, H., Audivert, F., and Alvarez, C. Suicide attempt by self-burning associated with ingestion of S-adenosylmethionine: a review of the literature and case report. J.Nerv.Ment.Dis. 2012;200:99-101.
  189. Furujo, M., Kinoshita, M., Nagao, M., and Kubo, T. S-adenosylmethionine treatment in methionine adenosyltransferase deficiency, a case report. Mol.Genet.Metab 2012;105:516-518.
  190. Coltorti, M., Bortolini, M., and Di Padova, C. A review of the studies on the clinical use of S-adenosylmethionine (SAMe) for the symptomatic treatment of intrahepatic cholestasis. Methods Find.Exp Clin Pharmacol 1990;12:69-78.
  191. Levkovitz, Y., Alpert, J. E., Brintz, C. E., Mischoulon, D., and Papakostas, G. I. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur.Psychiatry 2012;27:518-521.
  192. Konig, H. and Saal, J. [Quantitatively evaluated magnetic resonance tomography as a therapeutic follow-up of the nonsteroidal antirheumatic ademetionin: a pilot study in patients with gonarthrosis]. Rofo 1990;152:214-219.
  193. Carpenter, D. J. St. John’s wort and S-adenosyl methionine as “natural” alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit? Altern.Med.Rev. 2011;16:17-39.
  194. Fava, M., Rosenbaum, J. F., MacLaughlin, R., Falk, W. E., Pollack, M. H., Cohen, L. S., Jones, L., and Pill, L. Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant. J Psychiatr.Res 1990;24:177-184.
  195. Kaye, G. L., Blake, J. C., and Burroughs, A. K. Metabolism of exogenous S-adenosyl-L-methionine in patients with liver disease. Drugs 1990;40 Suppl 3:124-128.
  196. Freeman, M. P., Mischoulon, D., Tedeschini, E., Goodness, T., Cohen, L. S., Fava, M., and Papakostas, G. I. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J.Clin.Psychiatry 2010;71:682-688.
  197. De, Silva, V, El-Metwally, A., Ernst, E., Lewith, G., and Macfarlane, G. J. Evidence for the efficacy of complementary and alternative medicines in the management of fibromyalgia: a systematic review. Rheumatology.(Oxford) 2010;49:1063-1068.
  198. Kuzieva, G. Z., Kholmatova, N. M., Shevchenko, L. I., Khuzhakhmedov, ZhD, and Zavgorodniaia, S. V. [Lipid peroxidation and antioxidant system status in patients with acute myeloblast leukemia and toxic damage of the liver]. Lik.Sprava. 2009;(1-2):55-58.
  199. Rutjes, A. W., Nuesch, E., Reichenbach, S., and Juni, P. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane.Database.Syst.Rev. 2009;:CD007321.
  200. Gerards, M., Sluiter, W., van den Bosch, B. J., de Wit, L. E., Calis, C. M., Frentzen, M., Akbari, H., Schoonderwoerd, K., Scholte, H. R., Jongbloed, R. J., Hendrickx, A. T., de Coo, I. F., and Smeets, H. J. Defective complex I assembly due to C20orf7 mutations as a new cause of Leigh syndrome. J.Med.Genet. 2010;47:507-512.
  201. Panza, F., Frisardi, V., Capurso, C., D’Introno, A., Colacicco, A. M., Di, Palo A., Imbimbo, B. P., Vendemiale, G., Capurso, A., and Solfrizzi, V. Polyunsaturated fatty acid and S-adenosylmethionine supplementation in predementia syndromes and Alzheimer’s disease: a review. ScientificWorldJournal. 2009;9:373-389.
  202. Yang, J., He, Y., Du, Y. X., Tang, L. L., Wang, G. J., and Fawcett, J. P. Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. Clin.Ther. 2009;31:311-320.
  203. Jorm, A. F., Allen, N. B., O’Donnell, C. P., Parslow, R. A., Purcell, R., and Morgan, A. J. Effectiveness of complementary and self-help treatments for depression in children and adolescents. Med J Aust 10-2-2006;185:368-372.
  204. Glick, N. Dramatic reduction in self-injury in Lesch-Nyhan disease following S-adenosylmethionine administration. J.Inherit.Metab Dis. 2006;29:687.
  205. Hanje, A. J., Fortune, B., Song, M., Hill, D., and McClain, C. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr.Clin.Pract. 2006;21:255-272.
  206. Williams, A. L., Girard, C., Jui, D., Sabina, A., and Katz, D. L. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med 2005;28:132-139.
  207. Alpert J E, Papakostas G, Mischoulon D, Worthington J J, Petersen T, Mahal Y, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004;24(6):661-664.
  208. Chavez M. SAMe: S-Adenosylmethionine. Am J Health Syst Pharm. 2000;57(2):119-123.
  209. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L- methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002;76(5):1172S-1176S.
  210. Dey A, Caro AA, Cederbaum AL. S-adenosyl methionine protects ob/ob mice from CYP2E1-mediated liver injury. Am J Physiol Gastrointest Liver Physiol. 2007;293(1):G91-103.
  211. Fetrow CW, Avila JR. Efficacy of the dietary supplement S-adenosyl-L-methionine. Ann Pharmacother. 2001;35(11):1414-1425.
  212. Kim J, Lee EY, Koh EM, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis; an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin Ther. 2009; 31(12):2860-72.
  213. Lieber CS. Hepatic, metabolic, and nutritional disorders of alcoholism: from pathogenesis to therapy. Crit Rev Clin Lab Sci. 2000;37(6):551-584.
  214. Luo J, Li YN, Wang F, Zhang WM, Geng X. S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. Int J Biol Sci. 2010; 6(7):784-95.
  215. Mato JM, Lu SC. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology. 2007;45(5):1306-12.
  216. Morelli V, Zoorob RJ. Alternative therapies: Part 1. Depression, diabetes, obesity. Am Fam Phys. 2000;62(5):1051-1060.
  217. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskelet Disord. 2004 February 26;5:6.
  218. Rakel, D. Rakel Integrative Medicine, 2nd ed. Philadelphia, PA: Saunders Elsevier; 2007.
  219. Stern. Massachusetts General Hospital Comprehensive Clinical Psychiatry, 1st ed. Philadelphia, PA: Mosby, An Imprint of Elsevier; 2008.
  220. Center, S. A., Randolph, J. F., Warner, K. L., McCabe-McClelland, J., Foureman, P., Hoffmann, W. E., and Erb, H. N. The effects of S-adenosylmethionine on clinical pathology and redox potential in the red blood cell, liver, and bile of clinically normal cats. J Vet.Intern.Med 2005;19:303-314.
  221. Doshi, S., McDowell, I., Goodfellow, J., Stabler, S., Boger, R., Allen, R., Newcombe, R., Lewis, M., and Moat, S. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia. Metabolism 2005;54:351-360.
  222. Spijkerman, A. M., Smulders, Y. M., Kostense, P. J., Henry, R. M., Becker, A., Teerlink, T., Jakobs, C., Dekker, J. M., Nijpels, G., Heine, R. J., Bouter, L. M., and Stehouwer, C. D. S-adenosylmethionine and 5-methyltetrahydrofolate are associated with endothelial function after controlling for confounding by homocysteine: the Hoorn Study. Arterioscler.Thromb.Vasc.Biol. 2005;25:778-784.
  223. Shippy, R. A., Mendez, D., Jones, K., Cergnul, I., and Karpiak, S. E. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC.Psychiatry 11-11-2004;4:38.
  224. Alpert, J. E., Papakostas, G., Mischoulon, D., Worthington, J. J., III, Petersen, T., Mahal, Y., Burns, A., Bottiglieri, T., Nierenberg, A. A., and Fava, M. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin.Psychopharmacol. 2004;24:661-664.
  225. Schaller, J. L., Thomas, J., and Bazzan, A. J. SAMe use in children and adolescents. Eur.Child Adolesc.Psychiatry 2004;13:332-334.
  226. Santini, D., Vincenzi, B., Massacesi, C., Picardi, A., Gentilucci, U. V., Esposito, V., Liuzzi, G., La Cesa, A., Rocci, L., Marcucci, F., Montesarchio, V., Groeger, A. M., Bonsignori, M., and Tonini, G. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res 2003;23(6D):5173-5179.
  227. Papakostas, G. I., Alpert, J. E., and Fava, M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr.Psychiatry Rep. 2003;5:460-466.
  228. Li, N., Zhang, H. H., Wang, S. H., Zhu, W. M., Ren, J. A., and Li, J. S. S-adenosylmethionine in treatment of cholestasis after total parenteral nutrition: laboratory investigation and clinical application. Hepatobiliary.Pancreat.Dis.Int. 2002;1:96-100.
  229. Silveri, M. M., Parow, A. M., Villafuerte, R. A., Damico, K. E., Goren, J., Stoll, A. L., Cohen, B. M., and Renshaw, P. F. S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjects. Biol.Psychiatry 10-15-2003;54:833-839.
  230. Fava, M., Rosenbaum, J. F., Birnbaum, R., Kelly, K., Otto, M. W., and MacLaughlin, R. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr.Scand 1992;86:42-45.
  231. Rafique, S., Guardascione, M., Osman, E., Burroughs, A. K., and Owen, J. S. Reversal of extrahepatic membrane cholesterol deposition in patients with chronic liver diseases by S-adenosyl-L-methionine. Clin Sci (Colch.) 1992;83:353-356.
  232. Hardy, M. L., Coulter, I., Morton, S. C., Favreau, J., Venuturupalli, S., Chiappelli, F., Rossi, F., Orshansky, G., Jungvig, L. K., Roth, E. A., Suttorp, M. J., and Shekelle, P. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid.Rep.Technol.Assess.(Summ.) 2003;:1-3.
  233. Saletu, B., Anderer, P., Linzmayer, L., Semlitsch, H. V., Lindeck-Pozza, E., Assandri, A., Di Padova, C., and Saletu-Zyhlarz, G. M. Pharmacodynamic studies on the central mode of action of S-adenosyl-L-methionine (SAMe) infusions in elderly subjects, utilizing EEG mapping and psychometry. J Neural Transm. 2002;109:1505-1526.
  234. Saletu-Zyhlarz, G. M., Anderer, P., Linzmayer, L., Semlitsch, H. V., Assandri, A., Prause, W., Hassan Abu-Bakr, M., Lindeck-Pozza, E., and Saletu, B. Visualizing central effects of S-adenosyl-L-methionine (SAMe), a natural molecule with antidepressant properties, by pharmaco-EEG mapping. Int.J Neuropsychopharmacol. 2002;5:199-215.
  235. Fetrow, C. W. and Avila, J. R. Efficacy of the dietary supplement S-adenosyl-L-methionine. Ann Pharmacother. 2001;35:1414-1425.
  236. Labo, G. and Gasbarrini, G. B. [Therapeutic action of S-adenosylmethionine in some chronic hepatopathies]. Minerva Med 5-2-1975;66:1563-1570.
  237. Di Rocco, A., Rogers, J. D., Brown, R., Werner, P., and Bottiglieri, T. S-Adenosyl-Methionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov Disord 2000;15:1225-1229.
  238. Mantero, M., Pastorino, P., Carolei, A., and Agnoli, A. [Controlled double-blind study (SAMe-imipramine) in depressive syndromes]. Minerva Med 11-17-1975;66:4098-4101.
  239. Echols, J. C., Naidoo, U., and Salzman, C. SAMe (S-adenosylmethionine). Harv.Rev.Psychiatry 2000;8:84-90.
  240. Qin, B., Guo, S., Zhao, Y., Zou, S., Zhang, Q., Wang, Z., Zeng, W., and Zhang, D. A trial of ademetionine in the treatment of intrahepatic biliary stasis viral hepatitis. Zhonghua Gan Zang.Bing.Za Zhi 2000;8:158-160.
  241. Chavez, M. SAMe: S-Adenosylmethionine. Am J Health Syst.Pharm 1-15-2000;57:119-123.
  242. Porter, N. S., Jason, L. A., Boulton, A., Bothne, N., and Coleman, B. Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia. J.Altern.Complement Med. 2010;16:235-249.
  243. Frezza, M., Pozzato, G., Chiesa, L., Stramentinoli, G., and Di Padova, C. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. Hepatology 1984;4:274-278.
  244. Ribalta, J., Reyes, H., Gonzalez, M. C., Iglesias, J., Arrese, M., Poniachik, J., Molina, C., and Segovia, N. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo- controlled study with negative results. Hepatology 1991;13:1084-1089.
  245. Burrows, R. F., Clavisi, O., and Burrows, E. Interventions for treating cholestasis in pregnancy (Cochrane Review). Cochrane Database.Syst Rev 2001;4:CD000493.
  246. Papakostas, G. I., Cassiello, C. F., and Iovieno, N. Folates and S-adenosylmethionine for major depressive disorder. Can.J.Psychiatry 2012;57:406-413.
  247. Sarris, J. Clinical depression: an evidence-based integrative complementary medicine treatment model. Altern.Ther.Health Med. 2011;17:26-37.
  248. Sood A., Prasad K., Croghan I. T., Schroeder D. R., Ehlers S. L., Ebbert J. O. S-adenosyl-L-methionine (SAMe) for smoking abstinence: a randomized clinical trial. J Altern Complement Med 2012;18:854-859.
  249. Dording C. M., Mischoulon D., Shyu I., Alpert J. E., Papakostas G. I. SAMe and sexual functioning. Eur Psychiatry 2012;27:451-454.
  250. Plotkin L. L., Bespalov A. M., Smirnov D. M., Timchenko N. N., Shapovalova IuS, Konradi A. B. [Clinical signs of endothelial disorders in patients with severe sepsis]. Anesteziol Reanimatol 2012;:48-51.
  251. Strous R. D., Ritsner M. S., Adler S., Ratner Y., Maayan R., Kotler M., Lachman H., Weizman, A. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol 2009;19:14-22.
  252. Green T., Steingart L., Frisch A., Zarchi O., Weizman A., Gothelf D. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. J Neural Transm 2012;119:1417-1423.
  253. Feld J. J., Modi A. A., El-Diwany R., Rotman Y., Thomas E., Ahlenstiel G., Titerence R., Koh C., Cherepanov V., Heller T., Ghany M. G., Park Y., Hoofnagle J. H., Liang, T. J. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology 2011;140:830-839.
  254. Filipowicz M., Bernsmeier C., Terracciano L., Duong F. H., Heim M. H. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One 2010;5:e15492.
  255. Sun Q. F., Ding J. G., Wang X. F., Fu R. Q., Yang J. X., Hong L., Xu X. J., Wang J. R., Wu J. G., Xu D. Z. Efficacy and safety of intravenous stronger neo-minophagen C and S-adenosyl-L-methionine in treatment of pregnant woman with chronic hepatitis B: a pilot study. Med Sci Monit 2010;16:R9-14.
  256. Shilov V. V., Shikalova I. A., Vasil’ev S. A., Batotsyrenov B. V., Andrianov Alu. [Correction of metabolic disorders during treatment of alcohol-induced liver injuries in patients with acute alcoholic intoxication]. Klin Med (Mosk) 2013;91:45-48.
  257. Marchesini G, Bugianesi E, Bianchi G, et al. Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. Clinical Nutrition 1992;11:303-308.
  258. Gentile S., Persico M., Orlando C., Le Grazie C., Di Padova C., Coltorti M. Effect of different doses of S-adenosyl-L-methionine (SAMe) on nicotinic acid-induced hyperbilirubinaemia in Gilbert’s syndrome. Scand J Clin Lab Invest 1988;48:525-529.
  259. Micali M, Chiti D, Balestra V. Double-blind controlled clinical trial of SAMe administered orally in chronic liver diseases. Curr Ther Res 1983;33:1004-1013.
  260. Bresci G., Marchioro M. Effetti della SAMe sugli indici di funzionalità epatica in corso di epatopatia cronica. Confronto con placebo [Effects of SAMe on liver function tests in patients with chronic liver disease. A comparison with placebo]. Gazz Med Ital 1982;141:557-562.
  261. Di Palma D., Fiore M., Majoli M., et al. Prime acquisizioni sul trattamento delle epatiti acute con SAMe [First acquirements on the treatment of the acute hepatitis with SAMe]. G Mal Infett Parassit 1978;30:651-662.
  262. Jorge, A. D. Accion terapeutica de la SAMe en hepatitis aguda [Therapeutic action of the S-adenosyl-L-methionine in acute hepatitis]. Prensa Med Argent 1985;72:373-379.
  263. Musso A., Giacchino M., Vietti M., Vaccino P., Cerutti, A. [The use of silymarin and SAMe in the treatment of acute infective hepatitis in childhood]. Minerva Pediatr 1980;32:1057-1067.
  264. Miglio F., Stefanini G. F., Corazza G. R., D’Ambro A., Gasbarrini G. [Double-blind studies of the therapeutic action of S-Adenosylmethionine (SAMe) in oral administration, in liver cirrhosis and other chronic hepatitides]. Minerva Med 1975;66:1595-1599.
  265. Buzzelli G., Moscarella S., Focardi G., Dattolo P., Giusti A., Calviani L., Relli P., Gentilini, P. [Ursodeoxycholic hemisuccinate in the treatment of chronic active hepatitis. A controlled clinico-therapeutic study]. Minerva Med 1992;83:537-540.
  266. Mascio G, Guida L, Ferbo U, et al. Trattamento della steatosi epatica pura o associata ad altre epatopatie. Gazzetta Medica Italiana 1981;140:37-44.
  267. Pecoraro V., Bruno M., Giammona R. L’impiego terapeutico della SAMe (s-adenosil-l-metionina) nella epatite virale acuta [Therapy with SAMe (s-adenosyl-l-methionine) in acute viral hepatitis]. G Mal Infett Parassit 1979;31:390-394.
  268. Ideo G. [S-Adenosylmethionine: plasma levels in hepatic cirrhosis and preliminary results of its clinical use in hepatology. Double-blind study]. Minerva Med 1975;66:1571-1580.
  269. Belmont AD, Henkel RD, Ancira FU. [Parenteral SAMe as compared to a placebo in the treatment of alcoholic liver disease]. An Med Interna 1996;13:9-15.
  270. Medici V., Virata M. C., Peerson J. M., Stabler S. P., French S. W., Gregory J. F. III, Albanese A., Bowlus C. L., Devaraj S., Panacek E. A., Richards J. R., Halsted C. H. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res 2011;35:1960-1965.
  271. Frezza M. [A meta-analysis of therapeutic trials with ademetionine in the treatment of intrahepatic cholestasis]. Ann Ital Med Int 1993;8 Suppl:48S-51S.
  272. Di Benedetto P, Iona LG, Zidarich V. Clinical evaluation of S-adenosyl-L-methionine versus transcutaneous electrical nerve stimulation in primary fibromyalgia. Curr Ther Res 1993;53:222-229.
  273. Tavoni A., Jeracitano G., Cirigliano G. Evaluation of S-adenosylmethionine in secondary fibromyalgia: a double-blind study. Clin Exp Rheumatol 1998;16:106-107.
  274. Werneke U., Turner T., Priebe S. Complementary medicines in psychiatry: review of effectiveness and safety. Br J Psychiatry 2006;188:109-121.
  275. Rosenbaum J. F., Fava M., Falk W. E., Pollack M. H., Cohen L. S., Cohen B. M., Zubenko G. S. An open-label pilot study of oral S-adenosyl-L-methionine in major depression: interim results. Psychopharmacol Bull 1988;24:189-194.
  276. Chinchilla M. A., Vega Pinero M., Cebollada Gracia A., et al. Latencia antidepresiva y S-Adenosil-Metionina [Antidepressive latency and S-adenosylmethionine]. Anales de Psiquiatria 1996;12:67-71.
  277. . Cerutti PG, Savoini G, D’avola G, et al. Evaluation of the efficacy of s-adenosylmethionine in the treatment of depressive disorders: a controlled clinical trial against minaprine. Basi Razionali della Terapia 1989;19:591-595.
  278. Pancheri P., Scapicchio P., Chiaie R. D. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol 2002;5:287-294.
  279. Thomas C. S., Bottiglieri T., Edeh J., Carney M. W., Reynolds E. H., Toone B. K. The influence of S-adenosylmethionine (SAM) on prolactin in depressed patients. Int Clin Psychopharmacol 1987;2:97-102.
  280. Caruso I, Fumagalli M, Boccassini L, et al. Treatment of depression in rheumatoid arthritic patients. A comparison of S-adenosylmethionine (Samyr*) and placebo in a double-blind study. Clin Trials J 1987;24:305-310.
  281. Carrieri PB, Indaco A, Gentile S, et al. S-adenosylmethionine treatment of depressioin in patients with Parkinson’s disease: a double-blind, crossover study versus placebo. Curr Ther Res 1990;48:154-160.
  282. Janicak P. G., Lipinski J., Davis J. M., Altman E., Sharma R. P. Parenteral S-adenosyl-methionine (SAMe) in depression: literature review and preliminary data. Psychopharmacol Bull 1989;25:238-242.
  283. Delle Chiaie R, Pancheri P. [Combined analysis of two controlled multicentric, double blind studies to assess efficacy and safety of Sulfo-Adenosyl-Methionine (SAMe) vs. placebo (MC1) and SAMe vs. clomipramine (MC2) in the treatment of major depression]. J Ital Psicopatol 1999;5:1-16.
  284. Bombardieri G, Milani A, Bernardi L, et al. Effects of S-adenosyl-L-methionine (SAMe) in the treatment of Gilbert’s syndrome. Curr Ther Res 1985;37:580-585.
  285. Cacciatore L, Varriale A, Cozzolino G, et al. S-adenosylmethionine (SAMe) in the treatment of pruritus in chronic liver disease. Acta Therapeutica 1989;15:363-371.
  286. Binder T., Salaj P., Zima T., Vitek L. [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekol 2006;71:92-98.
  287. Lafuenti G., Plotti G., Nicolanti G., Gaglione R., Tibollo F. G., Mancuso S. [Evaluation of the obstetrical risk in pregnant women with intrahepatic cholestasis treated with S-adenosyl-L-methionine]. Recenti Prog Med 1988;79:420-423.
  288. Binder T., Salaj P., Zima T., Vitek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006;34:383-391.
  289. Roncaglia N., Locatelli A., Arreghini A., Assi F., Cameroni I., Pezzullo J. C., Ghidini A. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004;111:17-21.
  290. Roncaglia N, Locatelli A, Bellini P, et al. A randomized controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. Am J Obstet Gynecol 2000;182(1 pt 2):S167.
  291. Nicastri P. L., Diaferia A., Tartagni M., Loizzi P., Fanelli M. A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol 1998;105:1205-1207.
  292. Floreani A., Paternoster D., Melis A., Grella P. V. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. Eur J Obstet Gynecol Reprod Biol 1996;67:109-113.
  293. Zhu SS, Dong Y, Gan Y, et al. [Efficacy and safety of ademetionine for treatment of drug-induced liver disease in children]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010;24:136-138.
  294. Manzillo G, Piccinino F, Surrenti C, et al. Multicentre double-blind placebo-controlled study of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease. Drug Invest 1992;4 (Suppl. 4):90-100.
  295. Polli E, Cortellaro M, Parrini L, et al. [Pharmacological and clinical aspects of S-adenosylmethionine (SAMe) in primary degenerative arthropathy (osteoarthrosis)]. Minerva Med 1975;66:4443-4459.
  296. Kim J, Lee EY, Koh EM, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin Ther 2009;31:2860-2872.
  297. De Silva V, El-Metwally A, Ernst E, et al. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. Rheumatology (Oxford) 2011;50:911-920.
  298. Work Group for Major Depressive Disorder. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. American Psychiatric Association, May 2010 (Published October 2010). Available at: http://www.psych.org/guidelines/mdd2010.
  299. Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010;167:942-8.
  300. Ravindran AV, Lam RW, Filteau MJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord 2009;117 Suppl 1:S54-64.
  301. Nelson JC. S-adenosyl methionine (SAMe) augmentation in major depressive disorder. (Editorial). Am J Psychiatry 2010;167:889-91.
  302. Arnold O, Saletu B, Anderer P, et al. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Eur Neuropsychopharmacol 2005;15:533-43.
  303. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2006;:CD002235.
  304. Aggarwal R, Sentz J, Miller MA. Role of zinc administration in prevention of childhood diarrhea and respiratory illnesses: a meta-analysis. Pediatrics 2007;119:1120-30.
  305. Goren JL, Stoll AL, Damico KE, et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 2004;24:1501-7.
  306. Najm WI, Reinsch S, Hoehler F, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind crossover trial. BMC Musculoskelet Disord 2004;5:6.
  307. Charlton CG, Crowell B Jr. Parkinson’s disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol Biochem Behav 1992;43:423-31..
  308. Purohit V, Russo D. Role of S-adenosyl-L-methionine in the treatment of alcoholic liver disease: introduction and summary of the symposium. Alcohol 2002;27:151-4.
  309. Shekim WO, Antun F, Hanna GL, et al. S-adenosyl-L-methionine (SAM) in adults with ADHD, RS: preliminary results from an open trial. Psychopharmacol Bull 1990;26:249-53..
  310. Lieber CS. S-Adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr 2002;76:1183S-17S..
  311. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr 2002;76:1177S-82S..
  312. Saletu B, Anderer P, Di Padova C. Electrophysiological neuroimaging of the central effects of S-adenosyl-L-methionine by mapping of electroencephalograms and event-related potentials and low-resolution brain electromagnetic tomography. Am J Clin Nutr 2002;76:1162S-71S..
  313. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002;76:1158S-61S..
  314. Lieber CS, Packer L. S-Adenosylmethionine: molecular, biological, and clinical aspects—an introduction. Am J Clin Nutr 2002;76:1148S-50S..
  315. Soeken KL, Lee WL, Bausell RB, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract 2002;51:425-30..
  316. Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside–molecular basis of a pleiotrophic molecule. Am J Clin Nutr 2002;76:1151S-7S..
  317. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-Lmethionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in multicenter studies. Am J Clin Nutr 2002;76:1172S-6S..
  318. Hardy M, Coulter I, Morton SC, et al. S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Evidence Report/Technology Assessment Number 64. Agency for Healthcare Research and Quality, US Dept of Health and Human Services; 2002. AHRQ publication 02-E033. Rockville, Md. Available at: http://www.ahrq.gov/clinic/tp/sametp.htm.
  319. Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-3.
  320. Czap A. Beware the son of SAMe. Altern Med Rev 1999;4:73.
  321. Cowley G, Underwood A. Newsweek. July 5, 1999; pp. 46-50.
  322. Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 1991;20:294-302.
  323. Frezza M, Centini G, Cammareri G, et al. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepatogastroenterology 1990;37:122-5.
  324. Frezza M, Surrenti C, Manzillo G, et al. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study. Gastroenterology 1990;99:211-5.
  325. Podymova SD, Nadinskaia M. [Clinical trial of heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome]. Klin Med (Mosk) 1998;76:45-8.
  326. Loguercio C, Nardi G, Argenzio F, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol 1994;29:597-604.
  327. Diaz BA, Dominguez HR, Uribe AF. Parenteral S-adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases. An Med Interna 1996;13:9-15.
  328. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52.
  329. Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416.
  330. Volkmann H, Norregaard J, Jacobsen S, et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand J Rheumatol 1997;26:206-11.
  331. Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 1990;40:111-23.
  332. Tan SV, Guiloff RJ. Hypothesis on the pathogenesis of vacuolar myelopathy, dementia, and peripheral neuropathy in AIDS. J Neurol Neurosurg Psychiatry 1998;65:23-8.
  333. Castagna A, Le Grazie C, Accordini A, et al. Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAMe. Neurol 1995;45:1678-83.
  334. Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984;141:448-50.
  335. Glorioso S, Todesco S, Mazzi A, et al. Double-blind, multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 1985;5:39-49.
  336. Laudanno OM. Cytoprotective effect of S-adenosylmethionine compared with that of misoprostol against ethanol-, aspirin-, and stress-induced gastric damage. Am J Med 1987;83(5A):43-7.
  337. Tavoni A, Vitali C, Bombardieri S, Pasero G. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. Am J Med 1987;83:107-10.
  338. di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies. Am J Med 1987;83:60-5.
  339. Caruso I, Pietrogrande V. Italian double-blind, multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med 1987;83:66-71.
  340. Maccagno A, Di Giorgio EE, Caston OL, Sagasta CL. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med 1987;83:72-7.
  341. Vetter G. Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis. Am J Med 1987;83:78-80.
  342. Muller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. Am J Med 1987;83:81-3.
  343. Berger R, Nowak H. A new medical approach to the treatment of osteoarthritis. Report of an open phase IV study with ademetionine (Gumbaral). Am J Med 1987;83:84-8.
  344. Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 1987;83:89-94.
  345. Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine. Am J Med 1987;83:95-103.
  346. Vahora SA, Malek-Ahmasi P. S-adenosylmethionine in the treatment of depression. Neurosci Biobehav Rev 1988;12:139-41.
  347. Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry 1988;145:1110-4.
  348. Domljan Z, Vrhovac B, Durrigl T, Pucar I. A double-blind trial of ademetionine vs naproxen in activated gonarthrosis. Int J Clin Pharmacol Ther Toxicol 1989;27:329-33.
  349. Chawla RK, Bonkovsky HL, Galambos JT. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease. Drugs 1990;40:98-110.
  350. Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990;81:432-6.
  351. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990;147:591-5.
  352. Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992;44:257-62.
  353. Salmaggi P, Bressa GM, Nicchia G, et al. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom 1993;59:34-40.
  354. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand Suppl 1994;154:15-8.
  355. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994;154:7-14.
  356. Bradley JD, Flusser D, Katz BP, et al. A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis. J Rheumatol 1994;21:905-11.
  357. Fava M, Giannelli A, Rapisarda V, et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res 1995;56:295-7.
  358. Gaster B. S-adenosylmethionine (SAMe) for treatment of depression. Alternative Medicine Alert, 1999;12:133-5.
  359. Carney MW, Chary TK, Bottiglieri T, Reynolds EH. The switch mechanism and the bipolar/unipolar dichotomy. Br J Psychiatry 1989;154:48-51.
  360. Iruela LM, Minguez L, Merino J, Monedero G. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993;150:522.
  361. De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression. Curr Ther Res 1992;52:478-85.
  362. Janicak PG, Lipinski J, Davis JM, et al. S-adenosylmethionine in depression. A literature review and preliminary report. Ala J Med Sci 1988;25:306-13.
  363. Stramentinoli G, Gualano M, Galli-Kienle M. Intestinal absorption of S-adenosyl-L-methionine. J Pharmacol Exp Ther 1979;209:323-6.
  364. Investigator’s Brochure: Ademetionine 1,4-butanedisulfonate. Knoll Pharmaceuticals.
  365. Loehrer FM, Angst CP, Haefeli WE, et al. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol 1996;16:727-33.
  366. Loehrer FM, Schwab R, Angst CP, et al. Influence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine and methionine in healthy humans. J Pharmacol Exp Ther 1997;22:845-50.
  367. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-9.
  368. Perna AF, Castaldo P, Ingrosso D, et al. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J Nephrol 1999;12:230-40.
  369. FDA. List of orphan designations and approvals. Office of Orphan Products Development. Available at: www.fda.gov/orphan/designat/list.htm.
  370. Mock DM, Mock NI, Nelson RP, Lombard KA. Disturbances in biotin metabolism in children undergoing long-term anticonvulsant therapy. J Pediatr Gastroentereol Nutr 1998;26:245-50.
  371. Skyrme-Jones RA, O’Brien RC, Berry KL, Meredith IT. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. J Am Coll Cardiol 2000;36:94-102.
  372. Gamel JW, Barr CC. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111:1462-3.
  373. Awang DV. Parthenocide: demise of a facile theory of feverfew activity. J Herbs Spices Med Plants 1998;5:95-8.
  374. PremesisRx. Pharmacist’s Letter / Prescriber’s Letter 1999:15;151206.
  375. McKevoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  376. United States Pharmacopeial Convention, Inc., ed. Drug Information for the Health Care Professional. 19th ed. Englewood, CO: Micromedex Inc., 1999.
  377. Schulz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physician’s Guide to Herbal Medicine. Terry C. Telger, transl. 3rd ed. Berlin, GER: Springer, 1998.
  378. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  379. Foster S, Tyler VE. Tyler’s Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed., Binghamton, NY: Haworth Herbal Press, 1993.
  380. Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.
  381. Tyler VE. Herbs of Choice. Binghamton, NY: Pharmaceutical Products Press, 1994.
  382. Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
  383. Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.